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Summary In premenopausal women with advanced breast cancer the luteinising hormone-releasing hormone
agonist goserelin (Zoladex, ICI plc) will produce serum levels of oestradiol equivalent to those following
surgical oophorectomy or the menopause. This paper reports our further experience of using this drug in 75
premenopausal patients with advanced breast cancer. In addition to response rates, duration of response is
reported. An objective response was seen in 25 patients (33%), the median duration of which was in excess of
15 months. Seven patients (9%) showed a complete response to therapy; median duration > 37 months. There
was no significant difference in time to disease progression (Lee-Desu statistic 18.26, 1 d.f., P = 0.43) and
probability of survival (Lee-Desu statistic 3.41, 1 d.f., P = 0.07) between those patients assessed as having
either static disease, or those showing a partial response at six months. Response to therapy correlates
significantly with the oestrogen receptor status of the primary tumour (X2= 20.59, 6 d.f., P<0.005). The
modest side-effects, ease of administration and reversibility make this approach to therapy very attractive. This
is to be remembered in that 53% of patients had disease progression whilst receiving goserelin. These patients
thus avoided the unnecessary and irreversible morbidity associated with surgical oophorectomy. With the
proven efficacy and minimal morbidity associated with goserelin we believe there is no current role for surgical
oophorectomy in the management of premenopausal patients with advanced breast cancer.
The endocrine effects and clinical efficacy of the luteinising
hormone-releasing hormone (LH-RH) agonist goserelin
(Zoladex, ICI plc) as initial hormone therapy for premeno-
pausal advanced breast cancer patients have been previously
reported (Nicholson et al., 1984, 1985; Williams et al., 1986;
Walker et al., 1986). In a study of 53 premenopausal patients
we reported a response rate to goserelin of 31%; comparable
to our previous experience of surgical oophorectomy (Wil-
liams et al., 1986; Buchanan et al., 1986). Recently we have
described our experience of combining goserelin with the
anti-oestrogen tamoxifen (Robertson et al., 1989a; Walker et
al., 1989). Slightly lower levels of serum oestradiol were
recorded in those patients receiving combination therapy,
along with significant reductions in FSH as compared with
goserelin alone. An international multicentre trial is currently
underway to determine any clinical advantage of such a
combination.
The current paper updates our experience of treating 75
premenopausal advanced breast cancer patients with monthly
depot injections of goserelin 3.6 mg; particular address has
been given to both the duration of response and survival
probability.
Patients and methods
Seventy-five premenopausal patients with histologically pro-
ven advanced breast cancer have been treated by the admin-
istration of the gonadotrophin releasing hormone agonist
goserelin, subcutaneous implantation of a 3.6 mg depot
preparation at 28 day intervals. No patient had received
previous endocrine or cytotoxic therapies: all gave written
informed consent to the administration of the drug. The
median age of the patients on commencing therapy was 44
years (range 31-55), with the sites of disease as shown in
Table I. The major sites of metastatic disease in 54 patients
were: bone, 22 patients; pulmonary, 14 patients; bone and
pulmonary, 12 patients; visceral, six patients.
Initial examination included a full clinical examination
with documentation of all measurable disease and photo-
graphy where appropriate. A limited skeletal survey was
obtained in all patients. CT scans, isotope bone scans and
Table I Sites of disease in 75 patients receiving monthly, depot,
subcutaneous goserelin
No. ofpatients
Locally advanced primary 15
Locoregional recurrence 6
Locoregional recurrence with metastases 16
Metastatic disease 38
liver sonography were performed when clinically indicated.
Routine haematological and biochemical estimations were
also performed. Tumour steroid hormone receptor status was
known in 60 patients; the oestrogen receptor assays having
been performed by the Tenovus Institute, Cardiff using the
commercially available ER-enzyme immuno Lssay (Abbot
ER-Eia, monoclonal). Oestrogen receptor was considered
positive when a value greater than 5 fmol mg-' cytosol pro-
tein was obtained (Nicholson et al., 1981).
Patients were assessed for response according to UICC
criteria (Hayward et al., 1977). The British Breast Group
recommendation that the minimum duration of remission be
six months was also adhered to (British Breast Group, 1974).
Statistical methods
Actuarial survival analysis was performed using the statistical
package SPSSX-21 (SPSS, 1986) life table analysis which
calculates Gehan's generalised Wilcoxon rank test for cen-
sored data (Lee & Desu, 1972).
Results
Twenty-five of the 75 patients (33%) in whom disease was
assessable using the strict clinical criteria of the UICC
(Hayward et al., 1977) and the BBG (British Breast Group,
1974) were classified as having shown an objective response
to therapy of at least 6 months duration. A complete res-
ponse (CR) was seen in seven patients (9%), the median
duration of which was in excess of 37 months. Three of these
responders had stage III disease, while four had locoregional
recurrence; three of whom also had metastases (two pul-
monary, one bone). Static disease (SD) was seen in a further
11 patients (15%), whilst the remaining 39 patients (52%)
progressed (PD) within 6 months of starting goserelin. Dura-
tion of response is recorded in Table II. The probability of
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Figure 1 Probability ofdisease progression for patients receiving
goserelin.
disease progression in response to therapy is summarised in
Figure 1. There is no significant difference in the time to
disease progression between those patients assessed as having
shown a partial response (PR) to goserelin at 6 months, and
those that have statis disease (Lee-Desu statistic 0.63, 1 d.f.,
P = 0.43); survival does not significantly differ between these
two groups (Lee-Desu statistic 3.41, 1 d.f., P = 0.07). Patients
showing a complete response had a significantly increased
time interval to disease progression as compared to those
that showed a partial response (Lee-Desu statistic 6.69, 1 d.f.,
P = 0.009). The side-effects of goserelin included ameno-
rrhoea, hot flushes, vaginal dryness, and occasional nausea.
Primary tumour oestrogen receptor (ER) status was avail-
able in 60 patients (80%); 32 patients were ER positive, and
28 ER negative (see Table III). Nineteen of the 24 patients
responding to goserelin were ER positive, while three had
unknown receptor status. Ofthe seven patients that showed a
complete response, six had ER positive primary tumours.
Twenty-eight patients had tumours that were ER negative; 21
of these had progressive disease. The oestrogen receptor
status of the primary tumour correlates significantly with the
prediction of response to goserelin (X2 = 20.59, 6 d.f.,
P<0.005).
Discussion
Surgical oophorectomy has become the mainstay of treat-
ment for premenopausal patients with advanced breast
cancer since it was first introduced by Beatson at the end of
the last century (Beatson, 1896). This surgical approach
suffers many disadvantages in that treatment is palliative and
the majority of patients will not respond, thus exposing many
to unnecessary and irreversible morbidity (Kennedy et al.,
1964).
Table II Duration of response (months)
Response Number Duration
CR 7 (9%) 17, 36, 36 +, 37, 38, 48 +, 52 + (median 37 +)
PR 18 (24%) 7, 7 +, 8, 8 +, 9, 9, 9, 11, 14 +, 14, 14, 15 +,
16 +, 16, 18, 18 +, 22 +, 36 (median 14 +)
SD 11 (15%) 6,7,8,9,9, 10+, 10, 16+, 18,37,45+,
(median 10 +)
PD 39 (52%)
Table III Response to goserelin versus ER status of the primary
tumour
No. ofpatients
ER pos. ER neg. Unknown
Complete response 6 1
Partial response 13 2 3
Static disease 5 4 2
Progressive disease 8 21 10
X2=20.59, 6d.f., P<0.005.
Administration of the LH-RH agonist goserelin to pre-
menopausal advanced breast cancer patients produces a rapid
desensitisation of the pituitary gland to endogenous LH-RH,
with resultant falls in the circulating levels of LH and FSH
(Nicholson et al., 1984, 1985; Williams et al., 1986; Walker et
al., 1986). Castrate levels of oestradiol and progesterone are
produced within 3-4 weeks although a small group of
patients will shown recurrent suppressed peaks of oestradiol
(Williams et al., 1986). This ability to reduce serum oestra-
diol is not influenced by either the patients age or weight
(Nicholson & Walker, 1989). A theoretical limiting factor to
treatment with LH-RH agonists, as with radiation castration
is their inability to immediately suppress ovarian activity;
surgical oophorectomy produces castrate levels of oestradiol
within 2 to 7 days (Vermeulen, 1976; Beksac et al., 1983).
Despite these theoretical shortcomings we reported a re-
sponse to goserelin of 31% in a phase I study of 53 pre-
menopausal patients (Williams et al., 1986), a value that is
comparable to our previous experiences using surgical
oophorectomy (Buchanan et al., 1986). When we examined
the results of 23 assessable patients who had received a
combination of goserelin and the antioestrogen tamoxifen we
reported a 22% response, with a further 22% of patients
showing static disease (Robertson et al., 1989a).
It is apparent from this study of 75 patients that LH-RH
agonists are capable of achieving a significant objective re-
sponse of worthwhile duration in premenopausal advanced
breast cancer patients. We report an objective response rate
of 33%, with a median duration of response of 15 months
(range 7-52). Seven patients (9%) were classified as having
had a complete response, the median duration of which was
in excess of 37 months. A further 11 patients (15%) had
stable disease of at least 6 months duration (median duration
10 months). This group of patients have a similar survival to
those that show responsive disease to at 6 months; this
concords to our findings in patients treated with megesterol
(Robertson et al., 1989b). The remaining 39 patients (52%)
had disease progression within 6 months of starting treat-
ment.
It would appear that the presence of the oestrogen receptor
in the primary tumour may be predictive of a response to
medical oophorectomy using goserelin. This is in accordance
to our previous findings (Williams et al., 1986).
Goserelin is easily administered and produces an effective
but reversible castration. Objective remissions of worthwhile
duration are seen in a third of patients, comparable to sur-
gical oophorectomy but without its potential and irreversible
morbidity, psychological traumas and surgical risks. This is
particularly important in that 50% of patients will show no
response to the ovarian suppression. Monthly administration
also ensures a high patient compliance.
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